[Federal Register Volume 83, Number 61 (Thursday, March 29, 2018)]
[Notices]
[Pages 13519-13520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06321]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before April 30, 2018. Such
persons may also file a written request for a hearing on the
application on or before April 30, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with
[[Page 13520]]
respect to the promulgation and implementation of 21 CFR part 1301,
incident to the registration of manufacturers, distributors,
dispensers, importers, and exporters of controlled substances (other
than final orders in connection with suspension, denial, or revocation
of registration) has been redelegated to the Assistant Administrator of
the DEA Diversion Control Division (``Assistant Administrator'')
pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
5, 2017, Fisher Clinical Services, Inc., 700 A-C Nestle Way,
Breinigsville, Pennsylvania 18031-1522 applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Methylphenidate...................... 1724 II
Levorphanol.......................... 9220 II
Noroxymorphone....................... 9668 II
Tapentadol........................... 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form for testing, and clinical trials purposes only.
This authorization does not extend to the import of a finished Food and
Drug Administration (FDA) approved or non-approved dosage form for
commercial distribution in the United States.
Dated: March 15, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-06321 Filed 3-28-18; 8:45 am]
BILLING CODE 4410-09-P